Lack of modifying effects of atrazine and/or tamoxifen on thyroid carcinogenesis in rats pretreated with N-bis(2-hydroxypropyl)nitrosamine (DHPN).
The modifying effects of atrazine, and/or tamoxifen, on thyroid carcinogenesis were investigated in a rat two-stage carcinogenesis model following N-bis(2-hydroxypropyl)nitrosamine (DHPN) initiation. Five-week-old male F344 rats were given a single subcutaneous injection of DHPN (2800 mg/kg, body weight) or vehicle alone. Starting 1 week later, the animals were fed a diet supplemented with 0, 5, 50 or 500 ppm of atrazine, 500 ppm atrazine plus 5 ppm tamoxifen, or 5 ppm tamoxifen in the DHPN-treated groups, and 0 or 500 ppm of atrazine in the DHPN-untreated groups for 24 weeks. At autopsy major organs, including the thyroid, pituitary, liver, kidney, testis, epididymis, and brain, were collected and histopathologically examined. Body weights were significantly (P<0.05) decreased by the high doses of atrazine or tamoxifen, the effect being enhanced in combination. Relative thyroid weights were significantly increased (P<0.05) only in the tamoxifen-treated group and pituitary weights were elevated with 500 ppm atrazine plus tamoxifen (P<0.05). Relative liver weights were increased by the high dose of atrazine. However, the atrazine and/or tamoxifen treatments did not induce significant histopathological changes in the major organs, including the thyroid, nor cause significant changes in serum TSH levels. These results suggest that neither atrazine nor tamoxifen may promote thyroid carcinogenesis, alone as well as in combination.
Son
Hwa-Young
HY
Division of Pathology, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan.
Nishikawa
Akiyoshi
A
Okazaki
Kazushi
K
Lee
Kyong- Youl
K
Imazawa
Takayoshi
T
Hirose
Masao
M
D000818:Animals; D001280:Atrazine / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002273:Carcinogens / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D004435:Eating / Q000187:drug effects; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D006540:Herbicides / Q000627:therapeutic use*; D008297:Male; D009602:Nitrosamines / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D013629:Tamoxifen / Q000627:therapeutic use*; D013737:Testis / Q000473:pathology; D013963:Thyroid Hormones / Q000097:blood; D013964:Thyroid Neoplasms / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*
D002273:Carcinogens; D004965:Estrogen Antagonists; D006540:Herbicides; D009602:Nitrosamines; D013963:Thyroid Hormones; D013629:Tamoxifen; C037173:3-butenyl-(3-hydroxypropyl)nitrosamine; D001280:Atrazine